CLN-978
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
SLE
Conditions
SLE, SLE (Systemic Lupus)
Trial Timeline
Jan 21, 2025 → Dec 1, 2027
NCT ID
NCT06613360About CLN-978
CLN-978 is a phase 1 stage product being developed by Cullinan Therapeutics for SLE. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06613360. Target conditions include SLE, SLE (Systemic Lupus).
What happened to similar drugs?
20 of 20 similar drugs in SLE were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
6
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07041099 | Phase 1 | Recruiting |
| NCT06994143 | Phase 1 | Recruiting |
| NCT06613360 | Phase 1 | Recruiting |
| NCT05879744 | Phase 1 | Active |
Competing Products
20 competing products in SLE